Inhibiting TNF-α and p38 MAPK makes sense when taking their pro-inflammatory effects into consideration, but whether their associated inflammatory pathways are active and essential for driving disease progression in patients with CAD is more important in therapeutic design. The gene discussed is TNF; the disease is coronary artery disorder.